EUCTR2010-019598-13-IT进行中（未招募）不适用
A randomised, double-blind, dose-response, placebo-controlled, multicenter, phase IIA clinical study to evaluate the efficacy and safety of topical application of G.68.y/EtOH in patients with type 1 or type 2 diabetes with infected foot ulcers. - D.A.N.T.E
MOLTENI0 个研究点开始时间: 2011年12月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males or females of any race, aged 18 years or over. Females of childbearing potential must have a negative urine pregnancy test prior to commencing the study. 2. Diagnosis of type 1 or 2 diabetes. 3. A diabetic foot wound grade I or II and staging B or D, according to the TEXAS diabetic wound classification system. 4. Presence of infected foot ulcer of grade 2 (according to the PEDIS diabetic foot ulcer classification system), diagnosed via a clinic examination. 5. Presence of ulcer with an area from 2 to 15 cm2 and with a maximum diameter/length Ã?¢Ã?Â?Ã?¤ 4.6 cm measured by the VISITRAKÃ?¢Ã?Â?Ã?¢ system. 6. No concurrent illness indicating a life expectancy of less than 3 months. 7. Able to take oral medications. 8. Patients must provide their written informed consent to participate in the study. 9. Patients must be willing and able to comply with the protocol and study procedures. 10. Non-childbearing potential and childbearing potential female patients who agree to use an acceptable method of contraception for 60 days after the Treatment Visit (i.e., 60 days from the first and only application of the study drug) providing they are not pregnant or lactating. 11. Male patients must agree to use adequate methods of contraception for 30 days from the time of the Treatment Visit (i.e. 30 days from the first and only application of the study drug).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Female patients who are pregnant or breast-feeding. 2. Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to study treatment (Visit 0 or Visit 1). 3. Patients that cannot take Augmentin at the dosage stated in the protocol and according to the current Summary of Product Characteristics (SPC). 4. Ankle brachial systolic blood pressure index (Winsor Index) < 0.5 in the infected limb. 5. Clinical diagnosis of peripheral vascular disease (PVD) with ischemic ulcer, requiring percutaneous or surgery revascularization. 6. Ulcer probe to bone positive. 7. Prior anamnestic diagnosis of methicillin-resistant Staphylococcus aureus (MSRA) infection. 8. Any surgery planned in the study period, including scheduled amputation at the infected site. 9. Use of any other photodynamic therapy agents (e.g. Foscan and Photofrin) in the 5 days before study treatment (Visit 0 or Visit 1). 10. Use of any antibiotics (local or systemic) in a continuative way for a period âÂ?Â¥ 5 days prior to Treatment Visit (Visit 1). 11. Use of cortisone or other corticosteroids (local or systemic) in the 5 days before study treatment (Visit 0 or Visit 1). 12. Diagnosis of severe medical conditions such as severe heart failure or severe hepatic disease, according to the InvestigatorâÂ?Â?s judgment. 13. Existence of any surgical or medical condition which, in the judgement of the Investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug product. 14. Diagnosis of current cancer. 15. History of any medical or psychiatric conditions that, according to the Investigator, may increase the risks associated with the studyâÂ?Â?s participation or investigational product(s) administration. 16. History of any clinically significant photosensitive skin disorder. 17. Anamnestic diagnosis of alcohol dependence or substance dependence. 18. Known hypersensitivity to the TegadermTM patch. 19. Diagnosis of Acanthosis nigricans.
研究者
相似试验
已完成
不适用
A dose-response, double-blind, randomised placebo-controlled trial to estimate the dietary requirement for vitamin D in male and female adolescents aged 14-18 yearsTopic: Primary CareSubtopic: Not AssignedDisease: All DiseasesNutritional, Metabolic, EndocrineISRCTN40736890niversity of Surrey (UK)120
未知
2 期
A phase II/III study of TAC-202 in patients with chronic idiopathic urticariaPatients with Chronic idiopathic urticariaJPRN-jRCT2080222523Taiho Pharmaceutical Co., Ltd.300
进行中（未招募）
不适用
A clinical study to look at the safety, effectiveness and how COPD patients tolerate a new compound CHF6001 which will be inhaled daily for 28 days compared with existing treatment and placeboThe participants of this study have chronic obstructive pulmonary disease (COPD).EUCTR2012-001005-25-GBChiesi Farmaceutici S.p.A.65
已完成
3 期
A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids (FFA115285)10038716bronchial asthmaasthmaNL-OMON37429GlaxoSmithKline20
进行中（未招募）
不适用
A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.AsthmaEUCTR2010-020144-34-DEGlaxoSmithKline Research & Development Ltd330